Sign in or create an account to add this stock to your watchlist.
About LivaNova (NASDAQ:LIVN)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression. The company's product portfolio also includes various strategic portfolio initiatives, such as transcatheter mitral valve replacement, an implant device for the treatment of mitral regurgitation through the replacement of native mitral valve; VITARIA to treat heart failure through VNS; and ANTHEM-HFpEF to study autonomic regulation therapy in patients experiencing symptomatic heart failure with preserved ejection fraction, as well as treatment resistant depression. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LIVN
CUSIPN/A
Phone44-0-20-3325-0660
Debt
Debt-to-Equity Ratio0.03
Current Ratio1.85
Quick Ratio1.51
Price-To-Earnings
Trailing P/E Ratio25.36
Forward P/E Ratio26.31
P/E Growth2.62
Sales & Book Value
Annual Sales$1.01 billion
Price / Sales4.00
Cash Flow$5.7387 per share
Price / Cash14.58
Book Value$37.56 per share
Price / Book2.23
Profitability
EPS (Most Recent Fiscal Year)$3.31
Net Income$-25,080,000.00
Net Margins-1.99%
Return on Equity8.38%
Return on Assets5.99%
Miscellaneous
Employees4,500
Outstanding Shares48,440,000
LivaNova (NASDAQ:LIVN) Frequently Asked Questions
What is LivaNova's stock symbol?
LivaNova trades on the NASDAQ under the ticker symbol "LIVN."
How were LivaNova's earnings last quarter?
LivaNova PLC (NASDAQ:LIVN) announced its quarterly earnings data on Wednesday, May, 2nd. The company reported $0.68 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.65 by $0.03. The firm had revenue of $250.40 million for the quarter, compared to analysts' expectations of $245.18 million. LivaNova had a positive return on equity of 8.38% and a negative net margin of 1.99%. The company's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period last year, the firm earned $0.67 earnings per share. View LivaNova's Earnings History.
When is LivaNova's next earnings date?
What guidance has LivaNova issued on next quarter's earnings?
LivaNova issued an update on its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share (EPS) guidance of $3.50-3.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.51.
What price target have analysts set for LIVN?
7 brokers have issued 1 year target prices for LivaNova's stock. Their forecasts range from $50.00 to $104.00. On average, they anticipate LivaNova's stock price to reach $80.1667 in the next year. View Analyst Ratings for LivaNova.
What are Wall Street analysts saying about LivaNova stock?
Here are some recent quotes from research analysts about LivaNova stock:
- 1. According to Zacks Investment Research, "LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company's operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. " (5/17/2018)
- 2. Canaccord Genuity analysts commented, "We remain HOLD-rated on shares of LIVN in the wake of their announcement that the company would purchase the remaining part of ImThera – an early-stage company focused on neuromodulation to treat obstructive sleep apnea – that it does not already own. While the technology fits synergistically within LIVN’s strong neuromodulation franchise to some degree, the call point will be different than its current offering (ENTs vs. neurosurgeons). The firm thinks it can leverage its growing OUS neuromodulation sales presence to drive some near-term ImThera revenue (expectations not disclosed) in Europe; however, we expect contributions will be minimal for the next few years at least, primarily on the basis of current reimbursement coverage, or lack thereof, and need for long-term data to catalyze ENT surgeons to adopt the therapy, according to our due diligence." (12/5/2017)
- 3. Needham & Company LLC analysts commented, "LIVN announced that it is exploring strategic options for its low growth and low margin CRM business. This shouldn’t come as a huge surprise since management had previously hinted a potential sale of the CRM business. We think a CRM sale would increase LIVN’s revenue growth; the EPS impact hinges on price, CRM margins, and use of proceeds. We think a sale would be neutral to slightly dilutive if the proceeds were used for share repurchases and/or debt repayment though we note that there would likely be near-term hit to EPS between when the sale is announced and when LIVN is able to deploy the proceeds to offset any dilution." (9/14/2017)
Who are some of LivaNova's key competitors?
Some companies that are related to LivaNova include Varian Medical Systems (VAR), Sonova (SONVY), Masimo (MASI), Getinge Group (GNGBY), CONMED (CNMD), NxStage Medical (NXTM), AxoGen (AXGN), Natus Medical (BABY), Cutera (CUTR), Viewray (VRAY), Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT), Fonar (FONR) and Second Sight Medical Products (EYES).
Who are LivaNova's key executives?
LivaNova's management team includes the folowing people:
- Mr. Damien McDonald, Chief Exec. Officer and Director (Age 53)
- Mr. David S. Wise, Chief Admin. Officer (Age 63)
- Thad Huston, Chief Financial Officer
- Mr. Douglas J. Manko, Chief Accounting Officer (Age 44)
- Ms. Karen King, VP of Investor Relations & Corp. Communications
Has LivaNova been receiving favorable news coverage?
Media stories about LIVN stock have been trending somewhat positive recently, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. LivaNova earned a coverage optimism score of 0.07 on Accern's scale. They also assigned headlines about the company an impact score of 45.41 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are LivaNova's major shareholders?
LivaNova's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.50%), Franklin Resources Inc. (6.63%), Dimensional Fund Advisors LP (3.00%), OppenheimerFunds Inc. (2.49%), Wells Fargo & Company MN (1.85%) and Millennium Management LLC (1.48%). Company insiders that own LivaNova stock include Alfred J Novak, Daniel Jeffrey Moore, David S Wise, Hugh M Morrison, Jacques Gutedel, Sharon O'kane and Two SCA Equinox. View Institutional Ownership Trends for LivaNova.
Which major investors are selling LivaNova stock?
LIVN stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FIL Ltd, American Century Companies Inc., KBC Group NV, Redmile Group LLC, Dimensional Fund Advisors LP, Epoch Investment Partners Inc. and Bellevue Group AG. Company insiders that have sold LivaNova company stock in the last year include Alfred J Novak, Daniel Jeffrey Moore, David S Wise and Hugh M Morrison. View Insider Buying and Selling for LivaNova.
Which major investors are buying LivaNova stock?
LIVN stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Wells Fargo & Company MN, Point72 Asset Management L.P., Rothschild Asset Management Inc., BlackRock Inc., Neuberger Berman Group LLC, Millennium Management LLC and Allianz Asset Management GmbH. View Insider Buying and Selling for LivaNova.
How do I buy shares of LivaNova?
Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is LivaNova's stock price today?
One share of LIVN stock can currently be purchased for approximately $83.67.
How big of a company is LivaNova?
LivaNova has a market capitalization of $4.03 billion and generates $1.01 billion in revenue each year. The company earns $-25,080,000.00 in net income (profit) each year or $3.31 on an earnings per share basis. LivaNova employs 4,500 workers across the globe.
How can I contact LivaNova?
LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 44-0-20-3325-0660 or via email at [email protected]
MarketBeat Community Rating for LivaNova (LIVN)
MarketBeat's community ratings are surveys of what our community members think about LivaNova and other stocks. Vote "Outperform" if you believe LIVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
LivaNova (NASDAQ:LIVN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for LivaNova in the last 12 months. Their average twelve-month price target is $80.1667, suggesting that the stock has a possible downside of 4.19%. The high price target for LIVN is $104.00 and the low price target for LIVN is $50.00. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.43 | 2.43 | 2.43 | 2.43 |
| Ratings Breakdown: | 1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $80.1667 | $80.1667 | $78.1667 | $77.50 |
| Price Target Upside: | 4.19% downside | 8.39% downside | 6.54% downside | 8.15% downside |
LivaNova (NASDAQ:LIVN) Consensus Price Target History
LivaNova (NASDAQ:LIVN) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
LivaNova (NASDAQ:LIVN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
LivaNova (NASDAQ LIVN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.28%
Institutional Ownership Percentage: 83.38%
LivaNova (NASDAQ LIVN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/15/2018 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $84.66 | $84,660.00 | |  |
| 5/15/2018 | David S Wise | Insider | Sell | 1,500 | $84.48 | $126,720.00 | | |
| 5/9/2018 | Alfred J Novak | Director | Sell | 1,000 | $84.02 | $84,020.00 | | |
| 4/16/2018 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $86.24 | $86,240.00 | | |
| 4/16/2018 | David S Wise | Insider | Sell | 1,500 | $86.81 | $130,215.00 | | |
| 3/15/2018 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $88.31 | $88,310.00 | | |
| 3/15/2018 | David S Wise | Insider | Sell | 1,500 | $88.17 | $132,255.00 | | |
| 2/15/2018 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $83.32 | $83,320.00 | | |
| 1/16/2018 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $82.15 | $82,150.00 | | |
| 12/15/2017 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $80.80 | $80,800.00 | | |
| 11/29/2017 | Hugh M Morrison | Director | Sell | 1,830 | $88.00 | $161,040.00 | | |
| 11/22/2017 | Alfred J Novak | Director | Sell | 2,000 | $85.77 | $171,540.00 | | |
| 11/15/2017 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $81.39 | $81,390.00 | | |
| 10/16/2017 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $74.58 | $74,580.00 | | |
| 9/15/2017 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $68.55 | $68,550.00 | 57,296 | |
| 8/15/2017 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $60.76 | $60,760.00 | 58,296 | |
| 7/17/2017 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $61.55 | $61,550.00 | 56,437 | |
| 6/15/2017 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $60.80 | $60,800.00 | 57,437 | |
| 5/23/2017 | Sharon O'kane | Director | Buy | 1,000 | $58.58 | $58,580.00 | 1,000 | |
| 5/22/2017 | Alfred J Novak | Director | Sell | 1,000 | $58.49 | $58,490.00 | 12,020 | |
| 5/5/2017 | Hugh M Morrison | Director | Sell | 3,215 | $55.89 | $179,686.35 | 2,000 | |
| 4/17/2017 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $51.32 | $51,320.00 | 59,437 | |
| 3/15/2017 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $50.21 | $50,210.00 | 60,437 | |
| 9/22/2016 | Two S.C.A. Equinox | Major Shareholder | Sell | 185,000 | $61.54 | $11,384,900.00 | | |
| 9/21/2016 | Two S.C.A. Equinox | Major Shareholder | Sell | 391,379 | $60.69 | $23,752,791.51 | | |
| 9/16/2016 | Two S.C.A. Equinox | Major Shareholder | Sell | 75,213 | $59.86 | $4,502,250.18 | | |
| 9/13/2016 | Two S.C.A. Equinox | Major Shareholder | Sell | 25,408 | $60.02 | $1,524,988.16 | | |
| 9/8/2016 | Two S.C.A. Equinox | Major Shareholder | Sell | 208,000 | $60.52 | $12,588,160.00 | | |
| 8/9/2016 | Jacques Gutedel | Insider | Sell | 4,000 | $60.52 | $242,080.00 | 10,948 | |
| 5/24/2016 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $50.07 | $50,070.00 | 64,137 | |
| 5/19/2016 | Hugh M Morrison | Director | Sell | 3,600 | $48.00 | $172,800.00 | 5,215 | |
| 5/6/2016 | Alfred J Novak | Director | Sell | 4,000 | $51.12 | $204,480.00 | 13,020 | |
| 4/15/2016 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $54.81 | $54,810.00 | 64,437 | |
| 3/15/2016 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $56.88 | $56,880.00 | 65,437 | |
| 2/16/2016 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $56.88 | $56,880.00 | 66,437 | |
| 1/15/2016 | Daniel Jeffrey Moore | Director | Sell | 1,000 | $52.64 | $52,640.00 | 67,437 | |
| 12/15/2015 | Daniel Jeffrey Moore | Director | Sell | 2,500 | $53.97 | $134,925.00 | 68,437 | |
(Data available from 1/1/2013 forward)
LivaNova (NASDAQ LIVN) News Headlines
| Source: |
|
LivaNova (NASDAQ:LIVN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
LivaNova (NASDAQ:LIVN) Income Statement, Balance Sheet and Cash Flow Statement
LivaNova (NASDAQ LIVN) Stock Chart for Thursday, May, 24, 2018
Loading chart…
